Bayer's Share Price Is No Longer a Pure Litigation Play — But the Next Court Date Still Looms Large
Published on 08/05/2026 at 04:23 | Redaktion boerse-global.de
The market's reaction to Bayer's second-quarter numbers said as much about the future as it did about the past. The stock climbed 2.26 percent to 48.45 euros on the day of the release, a move that reflected not just a solid earnings beat but a growing conviction that the company's legal overhang is finally shrinking to a manageable size. The shares now trade 10.04 percent below their 52-week high of 53.86 euros, reached on July 3, and have gained 30.91 percent since the start of the year.
A profit beat that changes the narrative
The headline figures were undeniably strong. Group revenue rose 2.2 percent on a currency-adjusted basis to 10.872 billion euros in the second quarter, while adjusted EBITDA climbed 1.9 percent to 2.144 billion euros — comfortably ahead of the 1.94 billion euros analysts had penciled in. Perhaps more tellingly, core earnings per share of 0.95 euros came in roughly 26.5 percent above consensus, a figure JPMorgan's Richard Vosser singled out as the strongest data point in the entire report. The bank reaffirmed its "Overweight" rating with a price target of 50 euros, describing the quarter as operationally strong.
Bayer also confirmed its full-year guidance for currency-adjusted EBITDA before special items of between 9.6 and 10.1 billion euros, while improving its outlook for net financial debt, as deleveraging is progressing faster than originally planned. For a company that spent years generating headlines for all the wrong reasons — litigation risk, heavy debt, and a share price in freefall — that constitutes a notable turning point.
The legal calendar takes center stage
Yet the real catalyst for the stock's recent re-rating sits outside the income statement. On June 25, the US Supreme Court ruled 7-2 in "Monsanto v. Durnell" that federal law preempts state-level warning-label claims, a decision that stripped substantial legal ground from thousands of pending glyphosate lawsuits. Building on that ruling, Bayer announced on August 1 that it had reached settlement agreements covering a significant portion of the remaining US glyphosate cases, with a volume of 6.3 billion euros. The company has additionally carved its US glyphosate business into a separate entity called "Ruveon" to shield its other divisions from operational risk.
Should investors sell immediately? Or is it worth buying Bayer?
The next milestone arrives on August 19, when a court in St. Louis hears the final approval of the proposed glyphosate class settlement, valued at roughly 6.3 to 7.25 billion US dollars. Should the court greenlight the agreement, it would effectively close the final chapter of the legal saga that has weighed on Bayer's valuation for years. The company's share price has recovered impressively from its 52-week low of 25.09 euros, and the combination of the Supreme Court ruling, the settlement progress, and solid quarterly results provides more positive triggers than the current valuation appears to reflect.
Two divisions, two very different trajectories
The operational picture, however, remains a tale of two businesses. Crop Science delivered the standout performance, with segment earnings jumping 30.2 percent to 902 million euros in the second quarter, helped by the re-registration of the herbicide Dicamba in the US and stronger seed sales. Jefferies analyst Michael Leuchten acknowledged the strong gross margins in the agriculture division but remained cautious, keeping a "Hold" rating with a price target of 46 euros. His caution stems from the pharmaceutical arm, where the blood thinner Xarelto continues to erode under generic competition, with sales plunging 42 percent. That drag left Pharmaceuticals' total quarterly revenue at 4.46 billion euros, essentially flat.
The cancer drug Nubeqa provided a partial offset, surging 50 percent to 820 million euros. But the structural pressure on the pharma division remains the Achilles' heel of the entire investment case. CEO Bill Anderson has reiterated that a breakup of the group into Crop Science, Pharmaceuticals, and Consumer Health is not currently planned — a structural value catalyst that a segment of the market has long demanded remains off the table for now.
The cash flow question that decides everything
For investors, the ultimate test boils down to one metric: free cash flow. The second quarter showed a negative figure of 371 million euros, burdened by legal settlement payments totaling 2.5 billion euros in the first half. The company has already lowered its net financial debt target for 2026 to 29-30 billion euros, made possible by an equity investment from Apollo and a bond issuance of 5 billion US dollars. Whether the legal risks genuinely subside or merely transform into new payment obligations will determine whether the balance sheet repair holds.
Bayer at a turning point? This analysis reveals what investors need to know now.
The DZ Bank raised its fair value from 54 to 60 euros after the quarterly results, maintaining a "Buy" rating. The stock currently trades about 22.79 percent above its 200-day moving average, a technical indicator of the strength of the recent rally. With annualized volatility around 61.79 percent, however, the shares remain highly sensitive to any new legal developments.
The immediate path forward is clear: the August 19 hearing in St. Louis will determine whether the settlement receives final approval, and the next concrete test follows on November 3, when Bayer publishes third-quarter results and must demonstrate that free cash flow is genuinely stabilizing. If Crop Science maintains its recovery momentum and the glyphosate settlements stop draining cash, the stock's upward trajectory has room to continue. Should cash flow turn negative again — through additional settlement payments or a sharper Xarelto decline — the deleveraging story would stall, and the recent rally would lose its foundation.
Ad
Bayer Stock: New Analysis - 5 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
